SOFIA (Bulgaria), July 24 (SeeNews) - Bulgarian pharmaceuticals maker Biovet and its parent Huvepharma International intend to seek financing of 115 million euro ($133.5 million) by amending existing agreements with the European Investment Bank (EIB) and a syndicate of local and foreign lenders, Biovet said.